Across TCGA pan-cancer cohorts, ARSF mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ARSF data layer compared with 25 for mass-spec protein and 7 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARSF mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARSF expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.
CCRCC are the cancer types where ARSF mass-spec protein most reproducibly stratifies survival.